Pharma and healthcare: sector news on Monday 16 November 2026
Average tone +2.9 (slightly positive) across 3 companies with relevant coverage, from 12 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +4.5 | 6 | Coverage was mixed but leaned positive, with upheld quarterly growth guidance, reduced trial risk for Imfinzi and a new R&D centre. |
| GSK | +2.5 | 4 | Coverage was split. |
| Haleon | +1.8 | 2 | Coverage was light, with one of Haleon's brands winning an advertising award and RBC maintaining its Hold rating and 340p target. |
| Convatec | — | 0 | |
| Smith & Nephew | — | 0 |
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.